Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Current Leases (2016 - 2017)

Neurocrine Biosciences' Current Leases history spans 8 years, with the latest figure at $62000.0 for Q4 2017.

  • For Q4 2017, Current Leases fell 73.73% year-over-year to $62000.0; the TTM value through Dec 2017 reached $62000.0, down 73.73%, while the annual FY2017 figure was $62000.0, 73.73% down from the prior year.
  • Current Leases reached $62000.0 in Q4 2017 per NBIX's latest filing, down from $121000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $556000.0 in Q2 2015 to a low of $62000.0 in Q4 2017.
  • Average Current Leases over 5 years is $352900.0, with a median of $412500.0 recorded in 2013.
  • Peak YoY movement for Current Leases: surged 84.39% in 2013, then crashed 73.73% in 2017.
  • A 5-year view of Current Leases shows it stood at $416000.0 in 2013, then increased by 12.26% to $467000.0 in 2014, then decreased by 8.35% to $428000.0 in 2015, then plummeted by 44.86% to $236000.0 in 2016, then plummeted by 73.73% to $62000.0 in 2017.
  • Per Business Quant, the three most recent readings for NBIX's Current Leases are $62000.0 (Q4 2017), $121000.0 (Q3 2017), and $181000.0 (Q2 2017).